What NBE-Therapeutics does

NBE-Therapeutics AG is a Swiss biotech company founded in 2012 and headquartered in Basel, Switzerland, that develops next-generation antibody-drug conjugates (ADCs) for the treatment of solid tumors. Its integrated ADC platform combines four proprietary technologies: SMAC (sortase-enzyme mediated antibody conjugation) for site-specific, CMC-validated generation of homogeneous ADCs with precisely adjustable Drug-to-Antibody-Ratio; PNU-159682, a highly potent anthracycline derivative payload that induces immunogenic cell death and enables targeting of low-expressing antigens; Transpo-mAb mammalian cell display for functional antibody discovery using DNA transposition; and iADC, an immune-oncology ADC modality designed to drive durable anti-tumor immunity. The company maintains a pipeline of ADC product candidates targeting solid tumors at various preclinical stages of development.

Since December 2020, NBE-Therapeutics has operated as a wholly owned subsidiary of Boehringer Ingelheim following an acquisition valued at approximately $1.4 billion. Its business model is pre-commercial: the company is financed by its parent and prior venture investors (including Boehringer Ingelheim Venture Fund, PPF Group, and Novo Holdings, which together provided over $65 million in venture funding and $4 million in non-dilutive grants), and it generates revenue through R&D execution and pipeline development for the broader Boehringer Ingelheim ADC portfolio rather than direct product sales. A new NBE Therapeutics R&D center in Basel was announced in April 2025, and a COO was appointed in September 2025, both signals of continued investment by the parent.

Name

NBE-Therapeutics

Legal name

NBE-Therapeutics AG

Website

https://nbe-therapeutics.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

NBE-Therapeutics AG is a Basel-based biotech that develops next-generation antibody-drug conjugates (ADCs) targeting solid tumors for cancer patients, operating as a wholly owned subsidiary of Boehringer Ingelheim since its December 2020 acquisition.

Ownership category

akta.pro rank

Product category

Antibody-Drug Conjugates (Oncology Biopharmaceuticals)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

Keywords

• Antibody-drug conjugates
• Oncology therapeutics development
• Cancer immunotherapy
• Antibody conjugation technology
• Solid tumor treatments

Headquarters

HQ city

Basel

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Distribution channels1 record

Marketing channels4 records

Core offering

NBE-Therapeutics is a Swiss clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) for targeted treatment of solid tumor cancers. Its offering centers on four proprietary platform technologies — SMAC-Technology™ for site-specific conjugation, a PNU anthracycline payload, Transpo-mAb™ Display for antibody discovery, and an immune-oncology ADC (iADC) approach — used to progress a pipeline of ADC therapeutic candidates.

Product overview

NBE-Therapeutics is a privately-owned Swiss biotech company (acquired by Boehringer Ingelheim in December 2020) that develops next-generation antibody-drug conjugates (ADCs) for oncology treatment. The company operates an integrated ADC platform comprising four core proprietary technologies: SMAC-Technology™ for site-specific conjugation, PNU Anthracycline Payload (PNU-159682) for highly potent payload delivery, Transpo-mAb™ Display for antibody discovery, and iADC for immune-oncology effects. These technologies work together to enable the development of targeted cancer therapies that combine antibody selectivity with small molecule efficacy, with a pipeline of ADC candidates targeting solid tumors in various stages of clinical development.

Differentiator

Problem solved

Functional benefit

Products and services

• SMAC-Technology™

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Boehringer IngelheimcoreStrategic or Co-development Partner · 1 December 2020Boehringer Ingelheim acquired NBE-Therapeutics in December 2020, making NBE a wholly-owned subsidiary. Boehringer Ingelheim Venture Fund (BIVF) had previously been a lead investor prior to the acquisition. The acquisition strengthens Boehringer Ingelheim's antibody-drug conjugate portfolio. A new NBE Therapeutics R&D center was established in Basel in 2025.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• ADC Therapeutics: Swiss-based clinical-stage biotech developing antibody-drug conjugates for hematologic and solid tumors. Highly comparable as a similarly-sized ADC-focused company with proprietary payload and conjugation technologies targeting oncology.
• Mersana Therapeutics: Clinical-stage biotech developing next-generation ADCs with proprietary payload platforms (Dolasynthen, Immunosynthen) targeting solid tumors. Directly comparable ADC platform approach with differentiated conjugation and immune-engaging payload strategies similar to NBE's iADC.
• Heidelberg Pharma: German clinical-stage biotech developing ADCs based on proprietary amanitin payload chemistry for solid tumors. Comparable as an ADC platform company with novel payload technology addressing challenging target space, similar to NBE's PNU strategy.
• Sutro Biopharma: Clinical-stage biotech with proprietary cell-free protein synthesis platform enabling site-specific conjugation and ADC development. Comparable ADC platform company with proprietary discovery and conjugation technology targeting solid tumors.

Emerging players

• Tubulis: German biotech developing next-generation ADCs with novel linker and conjugation chemistries (P5 conjugation technology) for solid tumors. Comparable emerging ADC platform player with proprietary conjugation technology analogous to NBE's SMAC approach.
• Bolt Biotherapeutics: Clinical-stage biotech developing immune-stimulating ADCs (Boltbody ISACs) that combine tumor-targeting with immune activation. Closely comparable mechanism-of-action concept to NBE's iADC platform — combining ADC delivery with anti-tumor immune response.
• Pyxis Oncology: Clinical-stage biotech developing ADC and immune-engaging antibody therapeutics for solid tumors. Comparable as a focused ADC platform company building a pipeline around proprietary antibody-drug conjugate technologies in oncology.
• Bicycle Therapeutics: Clinical-stage biotech developing bicyclic peptide conjugates (Bicycles) and toxin conjugates for oncology. Comparable as an emerging targeted-conjugate company using novel chemistry approaches to address solid tumor targets with payload delivery.

Broad incumbents

• Daiichi Sankyo: Global pharmaceutical company and ADC leader (Enhertu, Datroway) with industry-leading DXd payload platform. Comparable as the dominant commercial-stage ADC incumbent competing for the same solid tumor opportunities NBE targets.
• Pfizer (Seagen): Pfizer's oncology franchise (including acquired Seagen) is a leading ADC commercial player (Adcetris, Padcev, Tukysa). Comparable as a broad incumbent with established ADC commercial infrastructure and pipeline that NBE ultimately leverages through Boehringer Ingelheim.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NBE-Therapeutics